drugset / Trial / NCT00655889

Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency

NCT00655889 ↗

Phase 2 Completed 13 enrolled Castle Creek Biosciences, LLC.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM in subjects with maxillary lesions who were treated in a previous study (IT-G-002, no NCT identification number)

Timeline

Start
2006-01
Primary completion
2008-04
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject azficel-T Cell therapy — Other

Indications

No indication recorded.